Table 1.
Baseline characteristics of patients receiving high or standard dosage enoxaparin prophylaxis
| All patients | High dose | Standard dose | |
|---|---|---|---|
| No | 278 | 127 | 151 |
| Male sex—no. (%) | 181 (65.1) | 82 (64.6) | 99 (65.6) |
| Age—yr | 59 (49–67) | 60 (51–69) | 58 (49–66) |
| Body mass index—kg/m2 | 27.7 (24.7–30.2) | 27.0 (24.2–30.2) | 28.1 (25.4–30.2) |
| Comorbidities*—n (%) | |||
| None | 119 (42.8) | 55 (43.3) | 64 (42.4) |
| One | 94 (32.8) | 41 (32.3) | 53 (35.1) |
| ≥ Two | 65 (23.4) | 31 (24.4) | 34 (22.5) |
| Haemoglobin—g/dL | 12.3 (10.9–13.4) | 12.3 (10.7–13.3) | 12.3 (11.1–13.5) |
| Platelet count—n/mm3 | 257 (182–348) | 259 (171–350) | 253 (185–341) |
| White blood cells—n/μL3 | 6.58 (4.84–10.13) | 6.58 (4.66–9.73) | 6.56 (5.28–10.25) |
| Creatinine—mg/dL | 0.84 (0.68–1.04) | 0.84 (0.68–1.00) | 0.86 (0.68–1.05) |
| Lactate dehydrogenase—U/L | 315 (253–427) | 306 (242–417) | 326 (255–448) |
| Prothrombin time—ratio | 1.15 (1.07–1.25) | 1.13(1.06–1.23) | 1.16 (1.09–1.27) |
| Activated partial thromboplastin time—ratio | 0.96 (0.88–1.04) | 0.97 (0.88–1.04) | 0.995 (0.88–1.04) |
| Fibrinogen—mg/mL | 550 (464–662) | 521 (442–638) | 602 (493–684) |
| d-dimer—µg/L | 1074 (589–2085) | 1088 (577–2195) | 1058 (597–1990) |
| C reactive protein—mg/dL | 8.69 (3.71–14.85) | 8.04 (3.55–14.40) | 9.40 (4.13–15.89) |
| Ferritin—µg/L | 1100 (586–1944) | 1117 (544–2118) | 1087 (642–1636) |
| Type of ventilation—n (%) | |||
| Ambient air | 18 (6.5) | 13 (10.2) | 5 (3.3) |
| Oxygen supplementation | 108 (38.8) | 56 (44.1) | 52 (34.4) |
| High flux nasal cannula | 14 (5) | 4 (3.1) | 10 (6.6) |
| Non-invasive ventilation | 85 (30.6) | 29 (22.8) | 56 (37.1) |
| Endotracheal intubation | 38 (13.7) | 21 (16.5) | 17 (11.3) |
| Missing data | 15 (5.4) | 4 (3.1) | 11 (7.3) |
Variables are expressed as median (IQR), unless differently specified
*Comorbidities include hypertension, diabetes, chronic lung disease (i.e. asthma, obstructive pulmonary disease, and bronchitis), active cancer, liver disease, systemic autoimmune diseases